We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Neuroprotective effects of magnesium in preterm infants - results of the ACTOMgSO<sub>4</sub> Study.
- Authors
Wink, K.
- Abstract
In spite of the great advances in the reduction of the mortality of high-risk infants, there has been no progress in reducing the prevalence of cerebral palsy (CP). A fundamental problem in efforts to prevent CP is a limited understanding of its causation. The ACTOMgSO4 Study is a multicenter, randomized trial accessing whether administration of magnesium sulfate to women at risk of preterm birth would reduce CP among very preterm infants. A total of 1,062 women at less than 30-week gestation who were expected to deliver within 24 hours were randomized either MgSO4 (1 g/h for 24 h) or placebo. The investigators found a 17% reduction in the 3 primary outcomes: total pediatry mortality (RR 0.83, 95% Cl 0.64- 1.09), CP in survivors (RR 0.83. 95% CI 0.66- 1.03), and 2 secondary outcomes: gross motor dysfunction (RR 0.51, 95% CI 0.29-0.91) and combined death or gross motor dysfunction (RB. 0.75, 95% CI 0.06 - 0.96). Neonatal morbidity, including intraventricular hemorrhage and periventricular leukomalacia was not reduced. No serious adverse effects were observed. The results of the well-conducted trial are encouraging, but the authors commend confirmation in other large trials before the routine prenatal use of magnesium sulfate as a neuroprotective agent for preterm infants.
- Publication
Trace Elements & Electrolytes, 2007, Vol 24, Issue 3, p161
- ISSN
0946-2104
- Publication type
Academic Journal
- DOI
10.5414/TEP24161